Dillan DiNardo

Mindstate Design Labs is a techbio platform and clinical-stage psychiatric therapeutics company using AI to precision-design psychoactive effects that drive targeted reintegrations of neural connectivity.

Dillan DiNardo is a biotechnology investor and operator with a background in venture capital. Prior to Mindstate Design Labs, he worked in a $1 billion venture fund, executing and managing more than fifty biopharma, medical device, and health tech investments ranging from pre-seed to publicly traded companies.

In addition to his investing capacity, he took an operating role in over a dozen early-stage spinout companies. His experience spans a variety of disease indications and modalities, with a focus on deep-tech applications such as cell and gene therapies.

Prior to his venture roles, he worked in finance for large international accounting and consulting firms as a transaction-focused consultant, covering the full investment life cycle from seed-stage startup funding to Fortune 500 mergers, acquisitions, and divestitures.

Dillan holds an MBA and a Bachelor’s in Finance from Robert Morris University.